Know Cancer

forgot password

A Phase II Study of BKM 120 for Patients With Recurrent Glioblastoma and Activated PI3K Pathway

Phase 2
18 Years
Open (Enrolling)

Thank you

Trial Information

A Phase II Study of BKM 120 for Patients With Recurrent Glioblastoma and Activated PI3K Pathway

For patients who will be having surgery, BKM will be taken orally for 8-12 days prior to
surgery. Prior to surgery they will have a FDG-PET scan and during surgery a sample of
tumor will be taken for research. Patients will resume oral BKM120 between 14 and 35 days
after surgery.

For patients who are not having surgery and post-surgery patients, BKM120 will be taken
orally for 28 days (1 cycle). Patients will continue on BKM120 as long as their brain tumor
does not get worse and they do not have severe or intolerable side effects.

During each cycle patients will have a physical examination, an assessment of tumor by MRI
or CT, routine blood tests, questionnaires to assess mood, and research blood samples for
genetic studies and other tests that will measure any additional effect of the study drug
and disease status. Participants may also be required to undergo a electrocardiogram and/or
MUGA scan to monitor heart function during the study.

Inclusion Criteria:

- Participants must be able to understand and be willing to sign a written informed
consent document.

- Subjects must be able to adhere to the dosing and visit schedules, and agree to
record medication times accurately and consistently in a daily diary.

- Participants must be at least 18 years old.

- Participants must have a estimated life expectancy > 8 weeks in the opinion of the

- Participants must have a Karnofsky performance status (KPS) ≥ 60. Nature of illness
and treatment history

- Participants must have histologically confirmed glioblastoma or variants.
Participants will be eligible if the original histology was low-grade glioma and a
subsequent histological diagnosis of glioblastoma or variants is made.

- Participants may have had treatment for no more than 1 prior relapse(NOTE: Relapse is
defined as progression following initial therapy (i.e., radiation ± chemotherapy)).
The intent therefore is that patients If the participant had a surgical resection
for relapsed disease and no antitumor therapy was instituted for up to 12 weeks, and
the participant undergoes another surgical resection, this is considered as a second
relapse. For participants who had prior therapy for a low-grade glioma, the surgical
diagnosis of a high-grade glioma will be considered the first relapse).

- Participants must have shown unequivocal evidence for tumor progression by MRI or CT

- For Cohort 2, CT or MRI within 14 days prior to start of study drug. MRIs should
include vascular imaging when possible. For Cohort 2, corticosteroid dose must be
stable or decreasing for at least 5 days prior to the scan. If steroids are added or
the steroid dose is increased between the date of the screening MRI or CT scan and
the start of treatment, a new baseline MRI or CT is required. For Cohort 1 subjects,
CT or MRI should be performed ideally within 14 days prior to study registration, but
because the screening MRI for this subset of subjects will not be used for evaluation
of response, it is acceptable for this MRI/CT to have been performed greater than 14
days prior to registration if unavoidable. Furthermore, for this same reason,
fluctuation in corticosteroid dose around this MRI does not warrant repeat scan so
long as there is documented unequivocal evidence of tumor progression available.

- Immunohistochemical or genetic analysis on tumor tissue from a prior surgery must
demonstrate activation of the PI3K pathway through one of the following: PIK3CA
mutation of PIK3R1 mutation, PTEN negativity (<10% of tumor cells staining) oh
immunohistochemistry, PTEN mutation (any), homozygous deletion of PTEN

- Participants must have failed prior radiation therapy and must have an interval of at
least 12 weeks from the completion of radiation therapy to study entry.

- Participants must have recovered to a grade 0 or 1 from the toxic effects of prior
therapy (with the exception of lymphopenia which is common after therapy with

- From the projected start of scheduled study treatment, the following time periods
must have elapsed: 4 weeks or 5 half-lives (whichever is shorter)from any
investigational agent, 4 weeks from cytotoxic therapy (except 23 days for
temozolomide and 6 weeks from nitrosoureas), 6 weeks from antibodies, or 4 or 5
half-lives (whichever is shorter) weeks from other anti-tumor therapies.

- Participants with prior therapy that included interstitial brachytherapy or
stereotactic radiosurgery must have confirmation of progressive disease based upon
nuclear imaging, MR spectroscopy, perfusion imaging or histopathology.

- Participants having undergone recent resection of recurrent or progressive tumor will
be eligible for Cohort 2 as long as the following conditions apply: a) They have
recovered from the effects of surgery; b)Residual disease following resection of
recurrent tumor is not mandated for eligibility. To best assess the extent of
residual disease postoperatively, an MRI or CT scan should ideally been performed no
later than 96 hours following surgery or at least 28-days postoperatively, but scans
performed outside of this window are considered acceptable if no alternative is
available. In either case, the baseline/screening MRI must be performed within 14
days prior to registration. If the participant is taking corticosteroids, the dose
must be stable or decreasing for at least 5 days prior to the scan. If steroids are
added or the steroid dose is increased between the date of the screening MRI or CT
scan and the start of treatment, a new baseline MRI or CT is required.

- Participants must have sufficient tissue from prior surgery for confirmation of
diagnosis and correlative studies. Submission of tissue is to occur within 30 days
after registration. The following amount of tissue is required: a) 25 unstained
formalin fixed paraffin embedded (FFPE) sections (standard 4-5 micrometer thickness
AND b)one of the following: i) At least 200 micrograms of frozen tissue OR ii)At
least 10 (preferably 20) unstained FFPE sections of 10 micrometer thickness OR iii)
At least 8 tissue cores from an FFPE block (200 micrometer total thickness of tissue
from a block with a total surface area of 0.5 cm2)

- Clinical laboratory tests within 14 days prior to enrollment meeting the criteria
listed in the protocol

- Cardiovascular assessment: baseline MUGA or Echocardiogram must demonstrate LVEF ≥ 50

- Electrocardiogram must demonstrate QTc interval of less than 480 msec

- Women are considered post-menopausal and not of child bearing potential if they have
had 12 months of natural (spontaneous) amenorrhea with appropriate clinical profile
(e.g., age appropriate, history of vasomotor symptoms) or six months of spontaneous
amenorrhea with serum FSH levels > 40 mIU/mL and estradiol < 20 pg/mL or have had
surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks
ago. In the case of oophorectomy alone, only when the reproductive status of the
woman has been confirmed by follow up hormone level assessment is she considered not
of child bearing potential.

- Women of child-bearing potential (WOCBP), defined as all women physiologically
capable of becoming pregnant, must use highly effective contraception (defined in
protocol) during study treatment and for 16 weeks after study discontinuation.

- Women of child-bearing potential must have a negative serum pregnancy test at
screening and within 48 hours prior to dosing with the study drug.

- Fertile males, defined as all males physiologically capable of conceiving offspring,
must use condom during study treatment and for 16 weeks after study discontinuation
and should not father a child in this period.

- Female partner of male study subject should use highly effective contraception while
receiving study agent and for 16 weeks after final dose of study therapy.

Cohort 1 Inclusion Criteria (In addition to the general eligibility criteria, participants
in the Cohort 1 preoperative portion of the study must meet the following criteria on
screening examination to be eligible):

- A participant who is deemed by the site Investigator to be an appropriate candidate
for surgical resection may be enrolled in the Cohort 1 preoperative study.

- There must be sufficient recurrent tumor to allow at least 400mg of tissue to be
collected ( 2 X 0.5 cm3) for pharmacokinetic and pharmacodynamic analysis.

- Immunohistochemical analysis on tumor tissue from an earlier surgery indicating pAKT
positive (1-2+ on a 0-2+ scale). Patients may also have one of the other criteria
listed for Cohort 2 but they are not mandatory.

Exclusion Criteria:

- Participants who have received prior treatment with a P13K inhibitor, AKT inhibitor,
mTOR inhibitor (e.g. rapamycin, MK2206, perifosine etc.).

- Participants who have received anti-angiogenic or anti-VEGF targeted agents (e.g.
bevacizumab, cediranib, aflibercept, vandetanib, XL184, sunitinib etc).

- Participants taking an enzyme-inducing anti-epileptic drug (EIAED): phenobarbital,
phenytoin, fosphenytoin, primidone, carbamazepine, oxcarbazepine, eslicarbazepine,
rufinamide, felbamate, and topiramate (only when daily dose exceeds 200 mg).
Participant must be off any EIAEDs for at least two weeks prior to starting study
drug. A list of EIAED and other inducers of CYP3A4 is provided in Table C-3 of
Appendix C of the protocol.

- Participants taking a drug known to be moderate and strong inhibitors or inducers of
isoenzyme CYP3A (Appendix C). Participant must be off CYP3A inhibitors and inducers
for at least two weeks prior to starting study drug. NOTE: participants must avoid
consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit
hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of
study drug and during the entire study treatment period due to potential CYP3A4

- Requirement of more than 8mg of dexamethasone daily.

- Participants taking drugs with known risk to promote QT prolongation and Torsades de
Pointes (refer to protocol).

- Participants receiving any other investigational agents.

- Current use of herbal preparations/medications, including but not limited to: St.
John's wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA),
yohimbe, saw palmetto, ginseng. Participants should stop using these herbal
medications 7 days prior to first dose of study drug.

- Current use of warfarin sodium or any other coumadin-derivative anticoagulant.
Participant must be off Coumadin-derivative anticoagulants for at least seven days
prior to starting study drug. Low molecular weight heparin is allowed.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to BKM120.

- History of intratumoral or peritumoral hemorrhage if deemed significant by the
treating physician.

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, chronic liver disease (e.g., cirrhosis, hepatitis), chronic renal disease,
pancreatitis, chronic pulmonary disease, or psychiatric illness/social situations
that would limit compliance with study requirements. Subjects must be free of any
clinically relevant disease (other than glioma) that would, in the Investigator's
opinion, interfere with the conduct of the study or study evaluations.

- Individuals with a history of a different malignancy except for the following
circumstances: if they have been disease-free for at least 3 years and are deemed by
the investigator to be at low risk for recurrence of that malignancy, individuals
with the following cancers are eligible if diagnosed and treated within the past 3
years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the

- Known diagnosis of human immunodeficiency virus (HIV) infection

- Participants with history of protocol specified mood disorders as judged by the
Investigator or a psychiatrist, or as result of participant's screening mood
assessment questionnaire

- Participants with diarrhea ≥ CTCAE grade 2

- Participant has active cardiac disease including any of the following: Angina
pectoris that requires the use of anti-anginal medications; Ventricular arrhythmias
except for benign premature ventricular contractions; Supraventricular and nodal
arrythmias requiring a pacemaker or not controlled with medication; Conduction
abnormality requiring a pacemaker; Valvular disease with document compromise in
cardiac function; Symptomatic pericarditis

- Participant has a history of cardiac dysfunction including any of the following:
Myocardial infraction within the last 6 months, documented by persistent elevated
cardiac enzymes or persistent regional wall abnormalities on assessment of LVEF
function; History of documented congestive heart failure (New York Heart Association
functional classification III-IV; c)Documented cardiomyopathy; d) Congenital long QT

- Participants with poorly controlled diabetes mellitus (glycosylated hemoglobin > 8%)
or poorly controlled steroid-induced diabetes mellitus (glycosylated hemoglobin > 8%)

- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea,
vomiting, diarrhea, malabsorption syndrome, or extensive small bowel resection).
Participants with unresolved diarrhea will be excluded as previously indicated.

- Participants who have undergone major systemic surgery ≤ 2 weeks prior to starting
study drug or who have not recovered from side effects of such therapy.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Cohort I: To evaluate PI3K pathway modulation of BKM120 in tumor tissue.

Outcome Description:

PI3-Kinase pathway modulation will be measured using immunohistochemistry analyses of unstained tumor tissue to identify PI3-Kinase mutations including PIK3CA mutations, PTEN mutations, and PTEN deletion by immunohistochemistry. Expression of pAKT will also be analyzed using immunohistochemistry.

Outcome Time Frame:

1 year

Safety Issue:


Principal Investigator

Patrick Y Wen, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute


United States: Food and Drug Administration

Study ID:




Start Date:

May 2011

Completion Date:

January 2015

Related Keywords:

  • Glioblastoma
  • BKM120
  • Brain tumor
  • Glioblastoma



Memorial Sloan-Kettering Cancer Center New York, New York  10021
Dana-Farber Cancer Institute Boston, Massachusetts  02115
Massachusetts General Hospital Boston, Massachusetts  02114-2617
University of California, San Francisco San Francisco, California  94143
University of California, Los Angeles Los Angeles, California  
Huntsman Cancer Institute, University of Utah Salt Lake City, Utah  84112
UT, MD Anderson Cancer Center Houston, Texas  77030